NodThera Announces Positive First-In-Human Data for Two Brain Penetrant NLRP3 Inflammasome Inhibitors
June 20, 2023
BOSTON, MA. – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from first-in-human studies